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The tissue-specific translation elongation factor eEF1A2 is a potential oncogene that is overexpressed in human ovarian cancer.
eEF1A2 is highly similar (98%) to the near-ubiquitously expressed eEF1A1 (formerly known as EF1-a) making analysis with
commercial antibodies difficult. We wanted to establish the expression pattern of eEF1A2 in ovarian cancer of defined histological
subtypes at both the RNA and protein level, and to establish the mechanism for the overexpression of eEF1A2 in tumours. We show
that while overexpression of eEF1A2 is seen at both the RNA and protein level in up to 75% of clear cell carcinomas, it occurs at a
lower frequency in other histological subtypes. The copy number at the EEF1A2 locus does not correlate with expression level of
the gene, no functional mutations were found, and the gene is unmethylated in both normal and tumour DNA, showing that
overexpression is not dependent on genetic or epigenetic modifications at the EEF1A2 locus. We suggest that the cause of
overexpression of eEF1A2 may be the inappropriate expression of a trans-acting factor. The oncogenicity of eEF1A2 may be related
either to its role in protein synthesis or to potential non-canonical functions.
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Ovarian cancer accounts for 4% of cases of female cancers; it has
the highest fatality-to-case ratio of all gynaecological cancers,
largely because the vast majority of cases are late-stage at
presentation. Tumours arising from the surface epithelium
represent the most common form of ovarian cancer. Although a
number of molecular mechanisms underlying ovarian tumour-
igenesis have been identified, a single model of progression has not
been described, possibly because of the heterogeneous nature
of ovarian carcinoma (Shih Ie and Kurman, 2004). Primary ovarian
adenocarcinomas are divided into four common distinct morpho-
logical subtypes: serous, mucinous, endometrioid, and clear cell.
Although clear-cell tumours are frequently confined to the ovaries
at presentation, they are associated with a poor prognosis and are
thus treated as high-grade neoplasms (Schwartz et al, 2002). The
incidence of clear-cell tumours among epithelial ovarian cancers is
around 10%. Clear-cell tumours tend to be resistant to platinum-
based chemotherapy, giving rise to a poor prognosis (Itamochi
et al, 2002).
Translation factor eEF1A2 is a tissue-specific variant of eEF1A1
(previously called EF-1a). While eEF1A1 is almost ubiquitously
expressed, expression of eEF1A2 is normally confined to muscles
and neurons (Lee et al, 1992; Knudsen et al, 1993). The gene
encoding eEF1A1 is on 6q13 and eEF1A2 on 20q13.3 (Lund et al,
1996). The encoded proteins are 92% identical and 98% similar.
Whereas lack of eEF1A2 gives rise to the wasted mouse phenotype
(Chambers et al, 1998), which involves motor neuron degeneration
(Newbery et al, 2005), inappropriate overexpression has now been
linked to cancer. Anand et al (2002) showed that eEF1A2, while
not normally expressed in ovary, is expressed in 30% of ovarian
tumours . The mechanism for the overexpression appeared to be
gene amplification in most, but not all, cases. Anand et al (2002)
were also able to demonstrate that ectopic expression of eEF1A2
in NIH3T3 cells gives rise to colony formation in soft agar and
increases growth rate. Furthermore, overexpression in rat fibro-
blasts enhances focus formation, and eEF1A2-expressing ES-2
ovarian cells and NIH3T3 cells injected into nude mice give rise to
tumour formation. There was however no information on which
types of ovarian tumours show overexpression of eEF1A2 and
expression was assessed at the RNA level only. eEF1A2 has been
identified in an expression microarray study as one of a number
of genes that are highly expressed (ca. fourfold) in clear cell
ovarian tumours than other histological subtypes of ovarian cancer
(Schwartz et al, 2002). We recently showed that EEF1A2 is also a
potential oncogene in breast tumours (Tomlinson et al, 2005).
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of ovarian tumours of defined histological subtypes. We have
generated and used a panel of antibodies that allow us to
distinguish between the highly related variants eEF1A1 (which is
expressed in normal breast and ovary) and eEF1A2 (which is
thought only to be expressed only in muscle and neurons under
normal circumstances) (Newbery et al, in preparation). We show
in a panel of ovarian tumours that while a high proportion of clear
cell carcinomas overexpress eEF1A2, a far smaller proportion
of serous, endometrioid and mucinous tumours have high levels of
eEF1A2 expression. Furthermore, we show that (1) DNA copy
number at the EEF1A2 locus is unrelated to expression level, (2)
there are no activating mutations in the eEF1A2 coding sequence
in tumours where there is overexpression in the absence of gene
amplification and (3) the methylation status of the EEF1A2 gene is
unrelated to expression level.
MATERIALS AND METHODS
Patient samples: ovarian tumours
Primary ovarian (HOV) tumour material and non-malignant
tissues were obtained from patients having undergone gynaecolo-
gical surgery in the Lothian University Hospitals NHS Trust.
Institutional ethical approval was granted for this work by the
Lothian University NHS Trust Medicine/Clinical Oncology Re-
search Ethics Subcommittee. Tissue samples were excised and
stored in liquid nitrogen. Non-malignant tissue samples were
derived from patients who underwent bilateral oophorectomies for
suspected malignancy, but were found to have benign histologies;
samples were collected from apparently normal contralateral
ovaries. Tumours were reviewed by subspecialist gynaecological
pathologists, and categorised according to stage and histological
type and grade.
Quantitative real-time reverse transcription–PCR
(RT–PCR)
RNA was prepared from ovarian samples and cell lines as
described previously (Sellar et al, 2003). Total RNA was isolated
from tumour and normal tissue using Qiagen RNeasy kits (Qiagen,
Crawley, UK). RNA was treated with DNase using DNAfree kit
(Ambion, Cambridgeshire, UK) and 1mg was used for RT–PCR
using Retroscript kit (Ambion). TaqMan Assay-on-Demand from
Applied Biosystems, Cheshire, UK was used for EEF1A2 (Assay;
Hs 00157325ml) and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; control; Hs 99999905ml). In a 10ml reaction volume per
well of a 394-well plate, 0.5ml of primers, 5ml of TaqMan PCR
Master Mix, no AmpErase UNG 10 , and 4.5ml of diluted cDNA
were added (Applied Biosystems). Real-time RT–PCR and the
quantification of RT–PCR products were performed and the
products analysed using an ABI Prism 7900HT Sequence Detection
System, and the appropriate software (SDS3.1) according to the
manufacturer’s instructions (Applied Biosystems).
Western blots
Protein lysates from cell lines were prepared using previously
published protocols (Gilmour et al, 2002); the same method was
used for primary tumour samples, but in these cases tissue was
initially homogenised in extraction buffer before determination of
protein content. Western blot analyses using 10mg protein were
carried out using standard protocols. The blots were incubated
with primary anti-eEF1A2 rabbit antibody diluted 1:200 in
blocking solution, as well as primary anti-GAPDH polyclonal
mouse antibody (Chemicon International, Hampshire, UK) diluted
1:10000. Blots were then incubated in the appropriate HRP
conjugated secondary antibody (Dako Cytomation, Cambridge-
shire, UK) at 1:500. Detection was performed using enhanced
chemiluminescence detection kit (Amersham Biosciences, Buck-
inghamshire, UK).
Immunohistochemistry
A computerised search of the archives of the Department of
Pathology was used to identify 168 cases of ovarian carcinoma of
the common epithelial types. Slides were retrieved and the
histological classification reviewed by a gynaecological pathologist.
Four representative areas of viable tumour tissue were identified
and marked on the slides, and the corresponding areas in the
paraffin blocks used as the source of tissue for the tissue
microarray (TMA). Tissue cores (0.6mm diameter) were sampled
from each of the four areas, and mounted into separate recipient
paraffin blocks by the use of a custom-made instrument (Beecher
Instruments, Silver Springs, MD, USA). In the ensuing paraffin
array blocks, the tissue cylinders were aligned and marked for
identification according to a chart. The recipient TMA blocks
were baked at 561C for 10min before sectioning, and 3mm paraffin
sections were cut by standard microtomy. A histoarray (CJ1)
produced by SuperBioChips (AMS Biotechnology, Oxfordshire,
UK) was also used. Formalin fixed, paraffin embedded, sections of
human normal tissue, tumour tissue and TMAs were deparaffi-
nised with xylene, rehydrated, treated with picric acid, and
microwaved in citric acid at pH 6. Slides were blocked in a 1:5
dilution of sheep serum for 30min at room temperature. Primary
anti-eEF1A2 rabbit antibody was used at a concentration of 1:10
diluted in phosphate-buffered saline (PBS), for 40min at room
temperature and secondary goat anti-rabbit IgG biotin conjugated
antibody (Dako Cytomation, Cambridgeshire, UK) was used at
1:200 at room temperature for 30min. Slides were incubated with
StreptABC complex/HRP (Dako Cytomation) at room temperature
for 30min and in diaminobenzidene (Sigma Fast DAB, Sigma,
Dorset, UK) for 2min at room temperature. Alternatively, after the
primary antibody step slides were washed in PBS and three drops
of ChemMate DAKO EnVision/HRP Rabbit/Mouse secondary
antibody (DAKO Cytomation) added to each slide. Slides were
incubated for 30min at room temperature and then washed in PBS.
The DAB-containing substrate working solution was prepared by
mixing 50 parts ChemMate Substrate Buffer with1 part ChemMate
DAB þ Chromogen (DAKO Cytomation). One millilitre of this
solution was added to each slide and incubated for 5min. Finally,
slides were counterstained in haematoxylin, dehydrated and
mounted in pertex.
Immunohistological scoring methods
The ovarian tumour histoarray (CJ1 SuperBioChips AMS Biotech-
nology, Oxfordshire, UK) and normal ovarian sections were given
a histoscore. For each score, the percentages of the tumour tissue
(excluding stroma) which stain strongly (3), moderately (2) and
faintly (1) were assessed. The Histoscore was calculated by
multiplying the percentage of tumour tissue staining by the score
in each category, and adding these values to give a maximum of
300. Expression in the TMAs was assessed using a modification of
the method of Tolivia et al (2006).
Statistical methods
Fisher’s exact test was used to test for associations between
positive protein expression and tumour subtypes of clear cell
carcinomas vs all other tumour types combined.
Mutation analysis
For mutation analysis of the EEF1A2 gene, primer pairs were
designed for each exon (see supplementary data). PCR was carried
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the cases of exons 1 and 8, that required the use of DyNAzyme EXT
DNA polymerase (Finnzymes, NEB, Hitchin, UK) with cycling
conditions consisting of an initial denaturation step at 941C for
5min followed by 32 cycles of 30s at 941C, 30s at the annealing
temperature and 30s at 721C (60s when using DyNAzyme). PCR
products were then sequenced using BigDye v3.1 (Applied
Biosystems) according to the manufacturer’s conditions.
Methylation analysis
Methylation analysis was carried out using bisulphite sequencing
of a 548bp region of the EEF1A2 CpG island. The EZ DNA
Methylation Kit (Zymo Research) was used to convert 1mg of DNA
from ovarian tumours HOV 104, 179, 548, and 557 and from
normal whole ovary samples 440 and 470 according to the
manufacturer’s protocol. The resulting DNA was amplified using
the following primers: 50-AGGGATTGGAAATTAGTAGATTT and
50- AAAAAAAATCCACCTATTAA and Roche Fast Start Taq DNA
polymerase. Cycling conditions were a 5min initial denaturation
step at 951C followed by 44 cycles of 951C for 30s, 521C for 30s,
and 721C for 90s. The converted PCR products were cloned into
the pCR2.1 vector using the TA Cloning Kit (Invitrogen) following
the manufacturer’s protocol. Clones (2–5 for each original DNA
sample) were sequenced as before and the results analysed using
BiQ Analyser software (http://biq-analyser.bioinf.mpi-inf.mpg.de/)
(Bock et al, 2005).
Quantitative real-time PCR analysis of copy number
For EEF1A2 DNA copy number analysis two sets of intronic
primers were designed (see supplementary data online). Primers
designed to amplify microsatellite loci in regions of chromosomes,
which are normally stable in ovarian cancers were used for
normalisation of total DNA amount. This was based on the method
of DNA copy number analysis used by Ginzinger et al (2000). For
determination of copy number at 20p primers from microsatellite
loci on 20p were used and normalised relative to D5S643.
Quantitative real-time PCR analysis was carried out using a MyiQ
Single Color Real-Time PCR machine (BioRad, Hemel Hempstead,
UK) and iQ SYBR Green Supermix (2 ) (BioRad). Standard
curves were conducted on 100ng DNA extracted from normal
blood that was serially diluted five times from 1:10 to 1:100000.
200ng of DNA from each tumour was used in a 25ml reaction.
Cycling conditions were an initial 8.5min denaturing step at
951C followed by 40 cycles of 951C for 30s, and 721C for 30s.
Fluorescent signal collection was carried out at elongation (721C).
A melt curve was included to confirm primer specificity and minus
DNA controls were included to confirm that there was no
contamination. Standard curves were used to determine the PCR
efficiency for each primer set. Primers were used at 200nM giving a
PCR efficiency of between 90 and 110%. EEF1A2 copy number was
then calculated using the (Pfaffl (2001) method of analysis. The
copy number of EEF1A2 in normal blood DNA was determined
using an average value from analysis of five different blood DNA
samples. The use of three microsatellite loci for normalisation
allowed for the exclusion of outlying values. Copy number at the
chromosome 20p microsatellites D20S804 and D20S819 was
calculated using the standard curve method of analysis (Applied
Biosystems User bulletin #3).
RESULTS
Expression analysis of ovarian tumours
We assessed RNA and protein samples taken from the same group
of ovarian tumours, all of which had been assessed for histological
subtype. Initially, we carried out real-time RT–PCR to assess the
level of expression of eEF1A2 mRNA in the tumour panel. The
results are shown in Figures 1A and B and Table 1; whereas three
out of the four clear cell tumours analysed (75%) had detectable
overexpression of eEF1A2, only four of the 18 serous tumours
(22%), five of the 12 endometrioid tumours (42%) and neither of
the mucinous tumours were overexpressing. Similar RT–PCR
analysis of a panel of ovarian cancer cell lines shows most cell lines
to overexpress eEF1A2 compared with a human leukaemic cell line
(HL60), with levels as high as 70-fold higher in the most extreme
instance (OVCAR5). The results are shown in Figure 1C.
We went on to use anti-peptide antibodies (Newbery et al, in
preparation) against eEF1A2. The antibodies were raised against
synthetic peptides, which were designed to maximise the
differences between eEF1A1 and eEF1A2. Western blots are shown
in Figure 2A. eEF1A2 protein is expressed at detectable levels in
most clear cell tumours (four out of five tumours analysed; 80%),
but only one out of 23 serous papillary tumours and two out of 11
endometrioid tumours. None of the five tumours with a mucinous
component had detectable eEF1A2 expression. Six of the seven
clear cell tumours analysed in total were overexpressing at either
the RNA or protein level or both. Unfortunately, only a few
tumours had both RNA and protein extracts available; of these,
only one (14) was positive at both RNA and protein levels; s 308,
80, 21, and 300 were negative at both RNA and protein level and s
9, 76, 88, 386, 77, and 5 had detectable expression at the RNA level
but not at the protein level. In this set of tumours, the expression
of eEF1A2 is highly significantly associated with the clear cell
carcinoma subtype when compared with all other tumour sub-
types combined (Po0.0012, Fisher’s exact test). The eEF1A2-
positive tumours represent less than 16% of our total tumour
panel, in contrast to the 26% figure obtained by Anand et al (2002).
This may simply represent the different frequency of clear cell
neoplasms in the two sets of samples, or reflect the higher numbers
of tumours that are positive at the RNA level, but which do not
express the protein. This may suggest that the mechanism of
overexpression of eEF1A2 in the tumours does not necessarily lead
to the production of a stable protein.
When we examined expression of eEF1A2 by Western blotting
in ovarian cancer cell lines we again found most cell lines to show
high levels of expression. The results are shown in Figure 2B. This
is in contrast with the results of Anand et al (2002), who found
overexpression in 4 out of 13 cell lines, but is in agreement with
previous results in our lab where we found most transformed cell
lines to express eEF1A2 (Tomlinson et al, 2005) and the study by
Joseph et al (2004) showing eEF1A2 expression in nine out of 10
cancer cell lines examined. The size of the eEF1A2 band appears to
shift slightly from one sample to the next suggesting the possibility
of post-translational modifications that vary between samples.
We then carried out immunohistochemistry. We wanted to
extend the Western blot analysis, but also to establish whether
there is any detectable expression in any cell type in the normal
ovary. Figure 3 shows the results obtained with normal tissue. The
only cells that were expressing eEF1A2 were luteinised stromal
cells, and the ovarian surface epithelium (OSE); there was no
staining in the secondary only control. We then analysed a
commercial TMA with 57 analysable tissue cores, and a TMA
constructed from local cases of ovarian carcinoma as described
above, containing a further 91 analysable cores of a single (i.e. not
mixed) histological subtype, 148 in total. It can be seen from
Figure 3 and Table 2 that the results are largely consistent with
those obtained by Western blotting. For the commercial array,
although one serous tumour and one mucinous tumour stained
moderately, the only epithelial ovarian tumours to display strong
staining with the anti-eEF1A2 antibody are clear cell carcinomas.
Moderate or strong expression was seen in 60% of clear cell
carcinomas by immunohistochemistry on this array. The associa-
tion between clear cell carcinomas and moderate or strong
expression of eEF1A2, in comparison to the other tumour types,
eEF1A2 in clear cell ovarian tumours
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array a less strong correlation with histological subtype was seen.
Only one tumour fell into the ‘strong’ category, with a histoscore of
229, and this was a clear cell tumour, but there were far more
negatively and weakly staining tumours overall; the total
percentage of tumours with moderate or strong histoscores was
5% for this TMA in contrast to the 19% for the commercial TMA.
Nevertheless, when the scores were combined, all three of the
tumours with a histoscore of 4200 were clear cell carcinomas.
DNA analysis of the EEF1A2 locus in ovarian tumours
Anand et al (2002) have previously shown that the EEF1A2 locus
is amplified in two out of three tumours they found to be
overexpressing eEF1A2, suggesting that amplification of the gene
may not be the only mechanism mediating overexpression. We did
not have access to cell lines from the tumours we had studied at
the RNA and Western level, but did have DNA, so we used a real-time
PCR method to estimate the copy number of the EEF1A2 locus.
This was based on the method of Ginzinger et al (2000), but
control primers were selected from regions that are normally
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Figure 1 (A) Real-time RT–PCR analysis of RNA from ovarian tumours. The amount of eEF1A2 message is shown normalised to GAPDH. Arrows
indicate clear cell carcinomas. Samples showing lower levels of expression are shown separately to display small amounts of expression at higher resolution.
(B) As in (A), but showing the lower part of the scale. (C) Real-time RT–PCR analysis of RNA from ovarian cancer cell lines. The amount of eEF1A2
message is shown normalised to GAPDH. The negative control is HL60, a leukaemia cell line.
Table 1 eEF1A2 expression in ovarian tumours
RNA Protein-Western
Tumour type
Number
analysed % positive
Number
analysed % positive
Clear cell 4 75 5 60
Serous 18 22 23 4
Endometrioid 12 42 11 18
Mucinous 2 0 5 0
GAPDH¼glyceraldehydes-3-phosphate dehydrogenase. Samples are scored as
positive at the RNA level if they have a score greater than 0.5 when normalised
to GAPDH (see Figure 1A).
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sgenomically stable in ovarian cancer; three sets were used in case
of between-tumour variation. The copy number of EEF1A2 was
estimated using primers within an intron to avoid amplification
of EEF1A1. We also estimated copy number at two loci on 20p,
to distinguish between amplification of 20q and polyploidy.
The results are shown in Figure 4; EEF1A2 was amplified at a
significant level (more than 2s.d. from normal DNA) in 12 of the 15
(80%) ovarian cancers expressing eEF1A2 at the RNA or protein
level. Only one of these, tumour HOV12, also had an increase in
copy number at 20p. However, all eight of those cancers not
expressing eEF1A2 also had copy numbers significantly exceeding
that found in normal diploid blood DNA. It is clear that there is no
obvious correlation between copy number and gene expression;
indeed, a non-expressing tumour, number HOV170, shows the
greatest EEF1A2 copy number. The similar pattern of copy number
changes between non-expressing and expressing tumours suggests
that gene amplification is not the primary mechanism underlying
the overexpression of eEF1A2.
We therefore, went on to establish whether the methylation
status of the EEF1A2 gene differs between ovarian tumours and
normal ovarian tissue. We used bisulphite sequencing to compare
the methylation profile of 548bp of the CpG island at the 50 end
of the EEF1A2 gene in DNA samples from normal ovary, from
tumours that do not express eEF1A2 and from overexpressing
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Figure 2 (A) Western blot analysis of protein extracts from ovarian
tumours. Sample numbers are the same as those shown in Figure 1A. The
same blot is shown having been exposed sequentially to eEF1A2 and
GAPDH antibodies with a stripping step in between each antibody. The
controls are HeLa, which expresses both eEF1A1 and eEF1A2,
lymphoblastoid cells (LB) which express only eEF1A1, and adult mouse
muscle, which expresses only eEF1A2. Clear-cell tumours are indicated by
bold underlined type. (B) Western blot analysis of protein extracts from
ovarian cancer cell lines. The negative control is a lymphoblastoid cell line
and the positive controls are HeLa, which we have previously found to
express eEF1A2 at high levels, and mouse muscle.
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Figure 3 Immunohistochemistry of normal ovary (A, B) and ovarian cancer (C–F) sections. Staining in the normal ovary can be seen to be confined to
luteinised stromal cells (N1) and low level expression in the ovarian surface epithelium (N2). HOV304 corresponds to one of the clear-cell tumors that was
also analysed by RT–PCR and T1 and T2 are clear-cell tumours from the histoarray. T3 is a negative staining tumour. Magnification  10.
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dinucleotides immediately 50 to the CpG island were methylated,
the CpG island itself was unmethylated in all cases, suggesting
that hypomethylation of the EEF1A2 gene in tumours is not a
mechanism for overexpression.
Finally, we sequenced the coding and untranslated regions of
the EEF1A2 gene in those tumours, which were overexpressing
eEF1A2, but which had low copy number (and were thus amenable
to analysis by sequencing without the potential complication of
sequence differences between gene copies). This group comprised
Table 2 Immunohistochemistry for eEF1A2 in different ovarian tumour types using a commercial TMA and an inhouse TMA
Tumor type Number analysed Negative % Weak % Moderate % Strong %
Clear cell 35 19 54 10 29 3 9 3 9
Serous 64 35 54 26 40 3 5 0 0
Endometrioid 38 29 76 9 24 0 0 0 0
Mucinous 11 6 54 4 36 1 10 0 0
Total 148 89 60 49 33 7 5 3 2
TMA¼tissue microarray. A histoscore of 0 is recorded as negative, between 1 and 100 as weak, between 101 and 200 as moderate and over 201 as strong.
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Figure 5 ‘Lollipop’ diagrams produced by BiQ Analyser. Open circles denote unmethylated CpG dinucleotides, while closed circles denote methylated
CpG dinucleotides. (A) Tumours 179 and 104, which do express eEF1A2 and show some methylation in CpG dinucleotides preceding the island, but no
methylation within the CpG island. (B) Tumours 308 and 470 which do not express eEF1A2. There are very few methylated CpGs either within the island
or preceding it. (C) DNA from two different normal whole ovaries. There is little methylation present at any CpG dinucleotide within the sequence.
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ssix tumours in total. All eight exons (including non-coding exon 1
and the 30UTR in exon 8) were sequenced together with flanking
intronic regions spanning splice sites. Apart from two established
single nucleotide polymorphisms (SNPs), the only sequence
alteration identified was a G to A substitution in exon 1 of tumour
183. This sequence alteration was present on both strands and is
not a known SNP; unfortunately DNA from normal tissue from the
same individual was not available, so it is not possible to establish
whether this is a tumour-specific change. However, given both that
exon 1 is noncoding, and that this tumour shows expression of
eEF1A2 at the RNA but not the protein level, the mutation is
unlikely to be of functional significance in terms of cancer. The
mechanism by which eEF1A2 is overexpressed in these tumours
thus remains elusive, but it is clearly of interest that over-
expression is able to occur in the absence of mutation or
demethylation, and that there is no correlation between over-
expression and amplification.
DISCUSSION
We have shown that, depending on the detection method used, up
to 75% of ovarian clear cell carcinomas show overexpression of
eEF1A2 at the protein level. At the RNA level, we find that 33% of
ovarian tumours in total overexpress eEF1A2, which is consistent
with the 30% figure reported by Anand et al (2002). In contrast to
the results of Anand et al (2002), we found some expression of
eEF1A2 in normal ovary, both in the OSE (from which tumours are
thought to arise), and in small nests of luteinised stromal cells. We
can not detect eEF1A2 expression in the vast majority of ovarian
tumours examined, however, which argues against the idea that
tumour overexpression is simply a feature of the cells from which
the tumours have arisen. Rather, it seems likely that inappropriate
expression of eEF1A2 contributes to tumorigenicity, as shown by
Anand et al (2002).
The finding that eEF1A2 overexpression at the protein level is
often associated with clear cell carcinomas is intriguing. Our
results are consistent with, and extend, those obtained from
microarray analysis by Schwartz et al (2002), who identified
eEF1A2 as one of a group of genes that are highly expressed in
clear cell carcinomas than other ovarian tumours. It is unclear why
eEF1A2 overexpression would be found particularly in clear cell
tumours. One possibility is that there is a link with p53; we found a
weak but not statistically significant association between eEF1A2
expression and p53 wild-type status in breast tumours (Tomlinson
et al, 2005), and clear cell carcinomas of the ovary normally
express p53. Alternatively, Schwartz et al (2002) showed a
tendency to upregulate stress response genes in ovarian clear-cell
tumours, which may be relevant given that eEF1A2 is a known
binding partner of peroxiredoxin Prdx1 (Chang and Wang, 2006).
The availability of a specific antibody that recognises eEF1A2,
but not eEF1A1, may be of use in a clinical setting once further
clinical correlations have been performed.
We have carried out a number of analyses of ovarian tumour
DNA to establish the mechanistic basis of the overexpression of
eEF1A2. Although amplification of the gene is seen in many
tumours there is no correlation between locus amplification and
gene expression, suggesting that this cannot be the sole underlying
mechanism of overexpression. Amplification was seen just as
frequently in tumours that do not express eEF1A2; it would be of
interest to examine the expression levels of other genes within this
amplicon. We sequenced the EEF1A2 gene from a number of
tumours with low copy number, but failed to find any mutations
that could be activating or otherwise lead to overexpression
(although it remains a possibility that there are mutations in
regulatory regions of the gene in some tumours); similarly, there
was no correlation between methylation status and expression. It is
clear therefore that overexpression does not depend on genetic or
epigenetic changes at the EEF1A2 locus; we suggest that the
overexpression may be mediated by the inappropriate expression
of a trans-acting factor in certain tumours. Microarray assays
could be informative in this regard.
It is still unknown why eEF1A2 should have oncogenic
properties in tissues in which the closely related eEF1A1 is already
expressed at high levels. It has been suggested that a straightfor-
ward increase in protein synthesis capacity could be responsible
(Thornton et al, 2003). It is also possible, however, that the two
eEF1A isoforms have subtly (or even substantially) different non-
canonical roles. Certainly, it has been demonstrated in myoblasts
that while eEF1A1 is pro-apoptotic (Ruest et al, 2002), eEF1A2 is
anti-apoptotic. Moreover, it has recently been shown that
co-expression of eEF1A2 and peroxiredoxin, Prdx1, renders
NIH3T3 cells dramatically resistant to apoptotic death induced
by exposure to oxidative stress (Chang and Wang, 2006). There are
numerous reports of the cytoskeletal modifying properties of
eEF1A1 (Condeelis, 1995; Edmonds et al, 1996); again, these might
differ from eEF1A1 to eEF1A2 and possibly relate to tumour
invasion and propensity to metastasize. Further in vitro and
clinical correlation studies should shed light on this. In the
meantime, eEF1A2 could provide a useful new diagnostic marker
for a sub-set of ovarian tumours, and ultimately a possible target
for therapy.
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